Navigation Links
Interleukin Genetics Appoints Todd Anthony Walker as Vice President, Marketing
Date:12/8/2008

WALTHAM, Mass., Dec. 8 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (Amex: ILI), today announced that Todd Anthony Walker has joined the Company as Vice President, Marketing. Mr. Walker will be responsible for all marketing activities for Interleukin Genetics and will be reporting to the Chief Executive Officer, Lewis H. Bender. Mr. Walker brings to the firm extensive marketing experience, as well as 20 years of industry-related experience.

Prior to joining Interleukin Genetics, Mr. Walker was the Worldwide Marketing Director for the Biopatch and OMNEX and synthetic sealants for Johnson & Johnson (JNJ) having worked in the Ethicon Inc., Jansen, Ortho-McNeil and PSGA divisions. Mr. Walker was responsible for developing global marketing strategies, establishing and influencing regional launches for products and building the framework for multigenerational product plans. Prior to joining Johnson & Johnson, Mr. Walker worked as a manager in various capacities with the Procter & Gamble Company.

"We are very pleased to have Todd Walker join Interleukin Genetics as Vice President, Marketing. He brings extensive experience in marketing of pharmaceutical and medical products to the consumer. Todd will have an office in Ada, Michigan, as well as Waltham Massachusetts, and he will spend significant time at our primary customer, Alticor," said Lewis H. Bender Chief Executive Officer at Interleukin Genetics.

Mr. Walker holds a Masters of Business Administration from Duke University's FUQUA School of Business, and a Bachelor's of Science Electrical Engineering Degree from Union College in Schenectady, New York.

About Interleukin Genetics

Interleukin Genetics, Inc. (Amex: ILI), is a healthcare company that specializes in the development of genetic biomarker tests for sale to the emerging personalized health market. The Company is focused on the future of health and medicine. Interleukin Genetics uses its leading genetics research and scientific capabilities to develop and commercialize innovative diagnostic and risk assessment genetic tests. These products could help to improve an individual's understanding of needed lifestyle changes or of therapeutic products that can be used to better manage their health. Interleukin Genetics has developed and commercialized genetic tests for risk assessment of coronary artery disease, periodontal disease, and general nutrition. Through its AJG subsidiary, the Company also currently offers an array of Nutraceutical and OTCeuticals(R) products, including Ginkoba(TM), Ginsana(R) and Venastat(R) which are sold at the nation's largest food, drug and mass retailers. Interleukin Genetics is headquartered in Waltham, MA. For more information about Interleukin Genetics and its ongoing programs, please visit www.ilgenetics.com.

Certain statements contained herein are "forward-looking" statements including statements regarding our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns and our ability to make progress in advancing our core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the risk of market acceptance of our products, the risk of technology and product obsolescence, delays in product development, the performance of our commercial partners, the availability of adequate capital, the actions of our competitors and other competitive risks, and those risks and uncertainties described in our annual reports on Form 10-K, our quarterly reports on Form 10-Q and other documents we file with, or furnish to, the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.


'/>"/>
SOURCE Interleukin Genetics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Interleukin Genetics Reports Third Quarter 2008 Financial Results
2. Interleukin Genetics to Present New Findings on Osteoporosis at the 58th Annual Meeting of the American Society of Human Genetics
3. Interleukin Genetics to Present New Findings at the 11th Cardiovascular Genomics and Atherosclerosis Symposium
4. Interleukin Genetics and Alticor Agree on Expansion of Distribution Channels for Genetic Tests
5. Interleukin Genetics Licenses its PST(R) Genetic Test to OralDNA Labs
6. Interleukin Genetics Announces Conference Call and Webcast to Discuss Second Quarter 2008 Business Results
7. Interleukin Genetics to Present at 2008 BIO International Convention
8. Interleukin Genetics to Present at the 13th International Conference on Periodontal Research
9. Interleukin Genetics Welcomes the Signing of the Genetic Information Nondiscrimination Act (GINA)
10. Interleukin Genetics to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference
11. Interleukin Genetics Announces Conference Call and Webcast to Discuss First Quarter 2008 Business Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... December 8, 2016 Oxford Gene ... customisable SureSeq™ NGS panel range with the launch of the ... cost-effective study of variants in familial hypercholesterolemia (FH). The panel ... detection on a single small panel and allows customisation by ... includes all exons for LDLR , P ...
(Date:12/8/2016)... ... December 08, 2016 , ... Microbial ... Technology Awards. uBiome is one of just six company finalists in the Health ... addition to uBiome, companies nominated as finalists in this year’s awards include Google, ...
(Date:12/8/2016)...  HedgePath Pharmaceuticals, Inc. (OTCQX: HPPI), a clinical ... to commercialize innovative therapeutics for patients with cancer, ... approved for trading on the OTCQX U.S. market. ... effective today, under the ticker symbol "HPPI." ... must meet high financial standards, follow best practice ...
(Date:12/8/2016)... SAN DIEGO , Dec. 8, 2016 /PRNewswire/ ... ), a leading commercial provider of clinically actionable ... cancer patients, announces that clinical data featuring its ... concordance to tissue biopsy for the detection of ... The results from research sponsored by Sara Cannon ...
Breaking Biology Technology:
(Date:12/2/2016)... PUNE, India , December 1, 2016 /PRNewswire/ ... Market by Authentication type (Fingerprint, Voice), Future Technology (Iris ... Vehicle), and Region - Global Forecast to 2021", ... be USD 442.7 Million in 2016, and is ... 2021, at a CAGR of 14.06%. ...
(Date:11/30/2016)... -- higi SH llc (higi) announced today the launch ... industry thought-leaders and celebrity influencers looking to encourage, ... steps to live healthier, more active lives. ... built the largest self-screening health station network in ... have conducted over 185 million biometric screenings.  The ...
(Date:11/29/2016)... , November 29, 2016 Nearly one billion matches ... Reading ... DERMALOG ... of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: The company's ...
Breaking Biology News(10 mins):